Beyond the heart: unveiling paroxysmal nocturnal hemoglobinuria in a patient with rheumatic heart disease
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253633Keywords:
Paroxysmal nocturnal hemoglobinuria, Rheumatic heart disease, Haemolytic anemiaAbstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disorder caused by a PIGA gene mutation, leading to glycosylphosphatidylinositol (GPI) anchor deficiency and uncontrolled complement activation. It causes intravascular hemolysis (IVH), thrombosis, and systemic complications. Rheumatic heart disease (RHD), associated with severe valvular pathology, can cause hemolytic anemia. Herein this case reports a 46-year female with RHD-associated aortic stenosis, regurgitation, chronic anemia, jaundice, and hemoglobinuria. Investigations showed hemolysis with elevated lactate dehydrogenase, indirect bilirubin, and reticulocytosis. Chronicity and severity prompted further evaluation. Flow cytometry revealed a significant PNH clone (40.15% in RBCs, >89% in WBCs), confirming complement-mediated hemolysis coexisting with RHD. This case highlights the diagnostic complexity of overlapping hemolytic mechanisms and underscores the importance of considering PNH in unexplained anemia and hemolysis, with early evaluation critical for optimizing outcomes in such rare clinical scenarios.
Metrics
References
Richards SJ, Painter D, Dickinson AJ, Griffin M, Munir T, Arnold L, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018. Eu J Haematol. 2021;107(2):211-8. DOI: https://doi.org/10.1111/ejh.13640
Oliver M, Patriquin CJ. Paroxysmal nocturnal hemoglobinuria: current management, unmet needs, and recommendations. J Blood Med. 2023:613-28. DOI: https://doi.org/10.2147/JBM.S431493
Ou Z, Yu D, Liang Y, Wu J, He H, Li Y, et al. Global burden of rheumatic heart disease: trends from 1990 to 2019. Arthritis Res Ther. 2022;24(1):138. DOI: https://doi.org/10.1186/s13075-022-02829-3
Manjunath CN, Srinivas P, Ravindranath KS, Dhanalakshmi C. Incidence and patterns of valvular heart disease in a tertiary care high-volume cardiac center: a single center experience. Indian Heart J. 2014;66(3):320-6. DOI: https://doi.org/10.1016/j.ihj.2014.03.010
Means RT Jr, Rodgers GM, Glader B, Arber DA, Appelbaum FR, Dispenzieri A, et al. Wintrobe’s clinical hematology. Chapter 32, Paroxysmal nocturnal hemoglobinuria. 15th edition. Philadelphia (PA): Wolters Kluwer. 2024.
Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-92. DOI: https://doi.org/10.1182/blood-2011-02-333997
Passey S, Purohit A. Detection of paroxysmal nocturnal haemoglobinuria clones in cases of deep vein thrombosis in a tertiary care centre, western Rajasthan. Indian J Med Res. 2022;156(3):543-8. DOI: https://doi.org/10.4103/ijmr.ijmr_2584_21
Athota S, Gopalan S, Arthur P, Jayaram A, Satish A. Deciphering Paroxysmal Nocturnal Hemoglobinuria: An Unusual Paradigm of Hemolytic Anemia. Cureus. 2024;16(8). DOI: https://doi.org/10.7759/cureus.67194
Manivannan P, Tyagi S, Pati HP, Saxena R. FLAER based assay according to newer guidelines increases sensitivity of PNH clone detection. Indian J Hematol Blood Transfus. 2020;36:526-34. DOI: https://doi.org/10.1007/s12288-019-01220-8
Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208-16. DOI: https://doi.org/10.1182/asheducation-2016.1.208
Sugiura T, Okumiya T, Kubo T, Takeuchi H, Matsumura Y. Evaluation of intravascular hemolysis with erythrocyte creatine in patients with aortic stenosis. Int Heart J. 2016;57(4):430-3. DOI: https://doi.org/10.1536/ihj.15-433
Downloads
Published
How to Cite
Issue
Section
